Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06629259

Guanfacine for Alcohol Use Disorder (AUD)

Led by Indiana University · Updated on 2026-05-11

200

Participants Needed

2

Research Sites

205 weeks

Total Duration

On this page

Sponsors

I

Indiana University

Lead Sponsor

N

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.

CONDITIONS

Official Title

Guanfacine for Alcohol Use Disorder (AUD)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Assigned as biological male or female at birth and identify as such
  • Meet current DSM V criteria for moderate to severe Alcohol Use Disorder
  • Be 18 years or older with a body mass index (BMI) of 18-35
  • Express desire to quit alcohol as determined by the SOCRATES scale
  • Have a positive urine test for alcohol on admission to study procedures
  • Able to provide informed verbal and written consent
  • Able to read English and complete study evaluations
  • Be in good health as verified by intake physical examination
Not Eligible

You will not qualify if you...

  • Meet criteria for moderate to severe Substance Use Disorder excluding alcohol and nicotine
  • Have a positive screen for substances of abuse excluding alcohol and nicotine
  • Be psychotic or severely psychiatrically disabled including suicidal, homicidal, or current mania
  • Require medical detoxification for physiological dependence on alcohol
  • Regular use of medications in last 6 months contraindicated with guanfacine XR
  • Be pregnant or breastfeeding
  • Use monophasic contraceptives
  • Have cardiovascular disease including high blood pressure
  • Have hypotension with sitting blood pressure below 100/50 mmHg
  • Have bradycardia with sitting heart rate below 60 bpm
  • Show clinically significant EKG conduction abnormalities including QTc over 470 msec for women and over 450 msec for men

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The Stark Neuroscience Building (Goodman Hall)

Indianapolis, Indiana, United States, 46202

Actively Recruiting

2

Rutgers School of Health Professionals

Newark, New Jersey, United States, 07107

Actively Recruiting

Loading map...

Research Team

H

Helen C Fox, PhD

CONTACT

M

Mitch Smith

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here